News and Trends 10 Nov 2016 UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […] November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 Evotec chooses Oxford as Proving Ground for Academia-Industry Bridge The German CRO has struck a deal with the University of Oxford to test a model framework for bringing academic research to the clinic faster. Evotec started out as a service provider in Hamburg, but thanks to former CEO Jörn Aldag, it has blossomed into a company that specializes in transforming newly discovered therapies into […] November 10, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 European Biotech is working hard to Beat back Melanoma Immunocore and Pierre Fabre have been representing Europe in this years’ Society for Melanoma Research Congress. This type of cancer may have its days counted! This week, scientists from around the globe met at the MRC to get an update on what’s going on in the fights against melanoma, the least common but most deadly skin […] November 10, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Nov 2016 British Artificial Intelligence will soon run Clinical Trials Artificial Intelligence can make clinical trials cheaper and faster, and this British start-up is about to start testing its technology to optimize drug development. BenevolentAI is a London start-up that specializes in artificial intelligence (AI); its BenevolentBio division, formerly Stratified Medical, applies AI to human health and biotech. Its baby is a technology that could speed […] November 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2016 These companies want to use Stem Cells to improve Drug Safety Axiogenesis and Metrion Biosciences will use stem cells to improve preclinical neurotoxicity and cardiac safety testing, a feat that can significantly reduce the time and cost of drug discovery and clinical development. Axiogenesis is a Biotech from Cologne, Germany, that develops cell lines derived from induced pluripotent stem cells (iPSCs) for preclinical applications. The company […] November 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2016 Swiss SynBio adds CRISPR to its Toolkit for new Specialty Chemicals Evolva is licensing the CRISPR patents of Emmanuelle Charpentier, in a deal with holding company ERS Genomics. This will grant access to the wonder gene-editing technology for one of the most important players in European SynBio. Headquartered in Switzerland, Evolva develops new ways to obtain ingredients and specialty chemicals with brewing and engineered microorganisms. Its […] November 8, 2016 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 Results from 45% of Clinical Trials are kept Secret A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […] November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 The Mind Behind the Artificial Pancreas that Could Change the Lives of Diabetics We had the opportunity to talk with Roman Hovorka, from The University of Cambridge, who’s working on a revolutionary medical device that can automatically improve glucose levels in people with type 1 diabetes. An artificial pancreas is a device that measures glucose levels and responds by injecting the right amount of insulin required at any […] November 7, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2016 Which Teams are taking home Lego Trophies from iGEM this year? The iGEM 2016 results are in! The world’s largest synthetic biology competition took place in Boston from the 24th to the 31st of October, and European teams took home the grand prizes in two of the three tiers, Postgraduate, Undergraduate and High School. The winners and their projects are listed below. Originally launched by Massachusetts Institute of Technology, […] November 3, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2016 NHS adopts Next-Gen Sequencing to Test for Birth Defects Despite a lawsuit from Illumina, Premaitha forged ahead with its NGS-based non-invasive prenatal test; the NHS just adopted it as a standard screen. With its seemingly infinite applications, next-generation sequencing (NGS) is a hot area, especially for diagnostics biotechs. A number have been founded in recent years to develop prenatal tests for birth defects, and […] November 2, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 Meet the Jellyfish Medtech seeking to disrupt the Collagen Market Jellyfish are a source of collagen: this is the idea behind the winner of Boost Cymru, a competition of the Life Sciences Hub Wales. We had a chat with Andrew Mearns-Spragg, CEO of Jellagen, about this promising startup. The jellyfish already has a place in Biotech’s hall of fame as the source of the gene for […] October 31, 2016 - 5 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […] October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email